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Background:  Stress-only (SO) SPECT is increasingly being used in symptomatic low-intermediate risk patients in order to minimize ionizing 
radiation. We tested whether ultra-low dose Tc-99m sestamibi (MIBI) utilizing new CZT-SPECT instrumentation might be as effective as usual-dose 
MIBI using Anger cameras with attenuation correction (AC) for pts selected for SO SPECT.
Methods:  Eligible patients included: exercise stress for > 6 mins, BMI < 35, sinus rhythm, no prior MI, no COM, and meeting 2009 RNI Appropriate 
Use Criteria. 250 patients (Group 1) underwent SO CZT SPECT (SpectrumDynamics, Haifa, Israel) for 12 - 15 mins in both upright and supine 
positions, and 250 pts (Group 2) were imaged with Anger SPECT (Cardio-MD, Philips Medical Systems, Milpitas, CA) for 18 - 22 minutes using AC 
(VantagePro). Group 1 pts received 1 - 4 mCi weight-based dose of MIBI and were imaged until ~16 cardiac counts were acquired. Group 2 pts 
received ~ 30 mCi MIBI. The primary outcome was diagnostic failure defined as need for confirmatory testing (alternate SPECT, PET, CTA, stress echo) 
< 30 days or unnecessary coronary angiography (UCA) (no stenosis >50%). Secondary outcomes were need for rest imaging, confirmatory testing, 
UCA, and any coronary event < 90 days.
Results:  62% were male, mean age was 58, mean BMI was 28, 35% had prior known CAD, 56% had chest pain and 36% had dyspnea as 
indications for testing. The mean MIBI dose for Grp 1 was 3.4+/-0.5 vs 31.3+/-3.3 for Grp 2. 13 of Grp 1 and 2 of Grp 2 scans were abnormal; 6/8 
Grp 1 pts referred to cath had same-setting PCI vs 0/1 Grp 2 pts. Less than 1% of either Grp had UCA, required confirmatory testing, or had events 
within 90 days. The only significant difference was that 17 (7%) Grp 1 pts required rest imaging vs 2 (1%) Grp 2 pts. Grp 1 pts received rest imaging 
same setting using 3X rest dose; Grp 2 pts came back ~24 hrs later for rest imaging using ~30 mCi MIBI.
Conclusion:  This study demonstrates that ultra-low dose SPECT can effectively evaluate selected pts with ~1 mSv dosimetry, indicating that 
new-generation SPECT is a formidable low-risk competitor to stress echo, coronary CT angiography, and conventional SO SPECT (~9 mSv) for testing 
appropriate lower CAD-likelihood patients.
